Additional file 1: of Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia

Table S1. Patient’s characteristic of gene expression cohort. Table S2. Patient’s characteristic ex vivo AZD-1775 treatment in single agent or in combination. Table S3. Quantitative analyses of G2/M checkpoint-related genes. Differential gene expression of 24 genes involved in the regulation of the G2/M checkpoint of primary leukemic cells in comparison to normal mononuclear cells (MNCs). In the table, the primary leukemic samples have been divided into three groups based on the ex vivo sensitivity to AZD-1775. Very good IC50 < 5uM; good IC50 < 10uM; poor IC50 > 10 uM. (PDF 253 kb